The Port Delivery System in the Paradigm

Controversies in Care: Experts assess the current role and future potential of Genentech’s Susvimo in patient care.

By: Michael Colucciello, MD, Dante J. Pieramici, MD, FASRS, Carl C. Awh, MD

Retinal Physician September 1, 2025 Vol 22, Issue September 2025 Page(s): 21-23

1

The Port Delivery System (PDS) with ranibizumab offers continuous drug delivery for neovascular age-related macular degeneration and diabetic macular edema.
2

PDS refills every 24 to 36 weeks, maintaining long-term vitreous levels of anti-VEGF, showing noninferior efficacy to monthly injections in trials.
3

The FDA approved PDS for diabetic macular edema in 2025, based on positive results demonstrating sustained vision improvements over two years.
4

Patient preference favors PDS due to reduced treatment frequency and sustained therapeutic effects compared to standard intravitreal injections.
5

Challenges in PDS adoption include initial higher endophthalmitis rates, but improved surgical techniques have significantly reduced complications.

1